Retrospective analysis of sorafenib combined with interferon α-1b, interleukin-2, and thalidomide as maintenance therapy in FLT3-ITD-positive acute myeloid leukemia.

ABSTRACT:

Objective

To evaluate the clinical efficacy of maintenance therapy with sorafenib combined with interferon α-1b, interleukin-2, and thalidomide (the ITI regimen) in patients with FLT3-ITD-positive acute myeloid leukemia (AML).

Methods

19 FLT3-ITD(+) AML patients were retrospectively analyzed, who received the sorafenib combined with ITI regimen as maintenance therapy after achieving remission at Affiliated Cancer Hospital of Zhengzhou University (January 2014-December 2024). Minimal residual disease (MRD) levels were monitored, and clinical outcomes, including survival duration, were assessed.

Results

This study included 19 patients (9 males, 10 females) with a median age at diagnosis of 59 years (range: 21-76). The median white blood cell count was 32.25×10⁹

SUBMITTER: Cheng C 

PROVIDER: S-EPMC12646904 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature